Roche struck a licensing agreement with Hansoh Pharma to acquire global rights to an early‑stage CDH17‑targeting antibody‑drug conjugate for colorectal cancer, paying an $80 million upfront and creating a potential $1.45 billion milestone structure. The deal gives Roche an additional ADC entry in solid tumor oncology and Hansoh a sizeable validation and funding pathway for its pipeline. Roche’s move illustrates continued pharma investment in ADCs as companies chase improved target selection and payload strategies to expand ADC efficacy in hard‑to‑treat solid tumors.